60 Degrees Pharmaceuticals, Inc.
SXTPHealthcare|Biotechnology|US
$0.59
-0.32 (-35.08%)
Tangible Book / Share
$0.84
Cash / Share
$0.39
Clinical Trials (6)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06656351 B-FREE Chronic Babesiosis Study | Chronic Babesiosis | P2 | Recruiting | 40 | Open-label | Tafenoquine 100mg |
| NCT06207370 Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis | Babesiosis | P2 | Recruiting | 33 | RCT, Double-blind | Tafenoquine |
| NCT03320174 Long-Term Safety Study of Tafenoquine | Healthy Volunteers | P2 | Completed | 600 | RCT, Double-blind | Tafenoquine |
| NCT04533347 Tafenoquine in Patients With Mild to Moderate COVID-19 | COVID 19 Disease | P2 | Completed | 86 | RCT, Double-blind | Tafenoquine Oral Tablet, Placebo |
| NCT02569827 Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore | Dengue Fever | P1P2 | Withdrawn | — | RCT, Double-blind | Celgosivir, Modipafant 50mg, Placebo, Modipafant 100mg |
| NCT06478641 Expanded Use in Persistent (B. Microti) Babesiosis | Persistent Babesiosis | AVAILABLE | — | — | Tafenoquine |